Delayed
Other stock markets
|
|
5-day change | 1st Jan Change | |
- EUR | -.--% | +0.33% | +0.33% |
2020 | Silmäasema Oyj Announces Management Members | CI |
2020 | Silmäasema Oyj Omits to Pay Dividend for the 2019 | CI |
Sales 2019 | 131 M 143 M | Sales 2020 * | - | Capitalization | 85.49 M 93.11 M |
---|---|---|---|---|---|
Net income 2019 | 3.00 M 3.27 M | Net income 2020 * | - | EV / Sales 2019 | 1,00x |
Net Debt 2019 | 46.15 M 50.26 M | Net cash position 2020 * | - 0 | EV / Sales 2020 * | - |
P/E ratio 2019 | 21,6x | P/E ratio 2020 * | Employees | - | |
Yield 2019 | - | Yield 2020 * |
-
| Free-Float | 2.36% |
More Fundamentals
* Assessed data
More news
More press releases
Managers | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | - | 2019 | |
Roope Sihvola
CTO | Chief Tech/Sci/R&D Officer | 49 | 2019 |
Anne Rantanen
SAM | Sales & Marketing | - | 2020 |
Members of the board | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | - | 2019 | |
Director/Board Member | 50 | 2014 | |
Harri Halonen
BRD | Director/Board Member | - | - |
Silmaasema Oyj is a Finland-based holding company of Silmaasema group, which offers ophthalmic goods and services. The Group is engaged in the retail of glasses, sunglasses and contact lenses, with a portfolio comprising such brands as Burberry, Dolce & Gabbana, Emporio Armani, Fendi, Furla, Gucci, Juicy Couture, Max Mara, Michael Kors, Pierre Cardin, Polaroid, Ray-Ban, Skaga, Tommy Hilfiger and Versace, among others. The Group also offers a range of healthcare services, such as eye surgery, eyelid and lens surgery, and ophthalmologist and optician services, among others. Additionally, it provides information on eye diseases and methods of treatment. The Group operates a chain of more than 120 stores and over 10 eye hospitals.
Sector
Other Specialty Retailers
1st Jan change | Capi. | |
---|---|---|
+0.33% | 93 M $ | |
-52.40% | 1 482 M $ | |
+1.84% | 737 M $ | |
+4.50% | 590 M $ | |
-1.16% | 493 M $ | |
+45.17% | 162 M $ | |
+95.11% | 162 M $ | |
+95.15% | 121 M $ | |
-30.06% | 107 M $ | |
+23.81% | 76 M $ |